Blog

The global healthcare ecosystem is currently traversing a structural inflection point where the traditional metrics of enterprise value, physical infrastructure, patient volume, and legacy software interfaces, are being systematically superseded by the strategic accumulation and utilisation of proprietary health data. In the current mergers and acquisitions landscape of 2024 and 2025, data has transitioned from a passive byproduct of clinical operations into a primary sovereign currency.&nbsp; &nbsp;&nbsp; This shift is predicated on the realisation that generic public data is fundamentally insufficient for the development of high-performance healthcare artificial intelligence tools. Such generic datasets frequently lack the clinical context, longitudinal depth and rigorous outcome labeling required to move AI from impressive laboratory demonstrations to reliable performance in real-world clinical settings.&nbsp; &nbsp;&nbsp; Consequently, the market is witnessing a profound "flight to quality," where buyers prioritise assets capable of medical record unification and structured extraction, recognising that a company possessing unified, AI-ready datasets is inherently more valuable than one with a sophisticated user interface but brittle underlying information architecture.Data as the Determinative Competitive Moat &nbsp;&nbsp; The current era of healthcare M&amp;A is defined by the transition of proprietary data from a supporting asset to the central source of competitive advantage. The structural decline in pharmaceutical productivity and the unsustainable rise in global healthcare spending have made the "AI-ready" dataset a strategic necessity. As buyers look beyond "flashy interfaces," they are placing their bets on companies that have mastered the technical and regulatory complexities of medical record unification and structured extraction. The value of these assets is underpinned by the five pillars of exclusivity, scale, quality, depth, and usability. While federated learning and synthetic data offer new pathways for collaboration and privacy, the primacy of high-fidelity, longitudinal real-world evidence remains unchallenged for clinical validation and regulatory approval.&nbsp; &nbsp;&nbsp; In the "decisive decade" ahead, the successful integration of data assets into the healthcare value chain will determine the winners in a market that has moved from "growth at all costs" to a rigorous "outcomes-plus-durability" paradigm. For strategic acquirers and financial sponsors alike, the ability to identify, value, and monetize proprietary health data is no longer merely a part of the M&amp;A toolkit. It is the very engine of the new healthcare economy.Source: <a href="https://www.healthcare.digital/single-post/proprietary-health-data-is-the-new-m-a-currency">https://www.healthcare.digital/single-post/proprietary-health-data-is-the-new-m-a-currency</a>

The Data Primacy Shift: Proprietary Health Datasets as the Sovereign Currency in Healthcare M&A

The structural determination of a transaction in the HealthTech and MedTech sectors, specifically the choice between a Share Purchase Agreement (SPA) and an Asset Purchase Agreement (APA), constitutes the most significant strategic pivot point for investors, founders and legal counsel.&nbsp; &nbsp;&nbsp; In an industry where valuation is predicated on a complex interplay of regulatory milestones, intellectual property (IP) robustness and high-fidelity patient data, the legal mechanism of transfer serves as the primary arbiter of post-closing operational risk and commercial viability.&nbsp; &nbsp;&nbsp; This report provides an analysis of these two instruments, detailing their divergent implications for regulatory compliance, data sovereignty, liability allocation and tax efficiency within the specific context of the United Kingdom’s legal and clinical landscape.<a href="https://www.healthcare.digital/single-post/navigating-share-purchase-agreements-versus-asset-purchase-agreements-in-the-healthtech-and-medtech">https://www.healthcare.digital/single-post/navigating-share-purchase-agreements-versus-asset-purchase-agreements-in-the-healthtech-and-medtech</a>

Navigating Share Purchase Agreements versus Asset Purchase Agreements in the MedTech and HealthTech Ecosystems

Nekson Advisors will be attending, speaking and chairing panels at leading healthtech and medtech events in the UK, Europe, North America and the Middle East throughout 2026.Q1 2026Digital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp; &nbsp; &nbsp;Q2 2026 &nbsp; NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp; &nbsp; HLTH Europe &gt; June 2026, Amsterdam, NetherlandsQ3 2026 &nbsp; HIMSS AI in Healthcare &gt; July 2026, New York, USABits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp; &nbsp; &nbsp;Q4 2026 &nbsp; World Health Summit 2026 &gt; October 2026, Berlin, Germany &nbsp; HealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp; HLTH USA 2026 &gt; October 2026, USA &nbsp; Barclays Health Elevate &gt; October 2026, London, UK&nbsp; &nbsp; Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp; &nbsp; &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, Germany &nbsp; &nbsp;Venture Capital World Summit &gt; December 2026 Toronto, CanadaOnline Meeting with Nelson AdvisorsPlease schedule an onlne meeting with the team using the link below:﻿<a href="https://scheduler.zoom.us/nelson-advisors/meeting">https://scheduler.zoom.us/nelson-advisors/meeting</a>

Nelson Advisors Conferences and Events 2026

Nelson Advisors advised the Clinic Letter AI founders &nbsp;on their sale to Mayden, backed by G Square Capital.CLAI is the ambient scribe built for the NHS. Ambient Voice Technology (AVT) solutions are being widely adopted by healthcare services due to their ability to significantly reduce manual data entry and give clinicians back valuable time that can be better spent on patient care. CLAI is a simple way to transcribe letters, generate clinical coding and automate follow up orders demonstrating up to 30% reduction in administration.The addition of CLAI strengthens Mayden’s mission to transform health and care by expanding their digital offering, helping to free up capacity for clinicians whilst enabling better outcomes for the people they support.Reece Donovan, CEO at Mayden says: “Welcoming CLAI to Mayden reflects our commitment to developing and supporting tools that make a meaningful difference to those delivering and accessing health and care services. CLAI will join our existing product portfolio – iaptus, theseus and bacpac – and deepens our ability to support services across the NHS, local authorities, VCSE’s and the private sector.At Mayden, our focus is supporting our customers with technology that improves the efficiency and quality of services, the working lives of professionals and the experience of care for the people they serve. That made the addition of CLAI a very simple decision. From the outset, it was clear we share the same values and a commitment to building technology collaboratively with our customers that drive real, tangible value. I’m excited about what we can achieve together.”James Balmain, Co-Founder at CLAI says: “Joining Mayden feels like a natural next step for us. As a small business, CLAI needed the help and support of a larger organisation and in Mayden we’re really confident we’ve found a brilliant owner. There is obvious value for us to add within the community mental health space, as providers begin to unlock the transformative power in AVT technologies – we can’t think of a more suitable use case than longer format mental health encounters.Mayden has a clear and well recognised commitment to building technology that genuinely supports the people using it – this focus on real-world impact is directly aligned with our sense of mission at CLAI. We’re delighted to be a part of the Mayden team and to continue on this journey together”.Source: <a href="https://www.mayden.com/blog/press-releases/clinicletter-ambient-scribe-joins-mayden/" data-mce-href="https://www.mayden.com/blog/press-releases/clinicletter-ambient-scribe-joins-mayden/">https://www.mayden.com/blog/press-releases/clinicletter-ambient-scribe-joins-mayden/</a>

Nelson Advisors advised the Clinic Letter AI founders  on their sale to Mayden, backed by G Square Capital

Nelson Advisors served as exclusive advisors to Wellola on their sale to &nbsp;Mayden, backed by G Square Capital.Wellola was founded in 2016 by clinical entrepreneurs Sonia Neary and Dr Greg Martin, with the simple mission to build a patient engagement platform that empowers healthcare teams to deliver seamless, secure, and personalised digital care.Portasana® is a fully integrated patient engagement platform that supports NHS and international healthcare providers in improving access, enabling safe self-management, and reducing pressure on clinical teams. The platform connects with EPRs including Rio and EMIS, the NHS App, and wider clinical systems, offering a configurable suite of modules such as appointments, letters, messaging, forms, symptom tracking, remote monitoring, surveys and condition-specific journeys to support proactive, remote care.&nbsp;The addition of Wellola strengthens Mayden’s mission to transform health and care by expanding its digital offering and combining two organisations with shared values. Together, Mayden and Wellola are committed to empowering clinicians, improving patient outcomes, and making healthcare systems more efficient and sustainable.Reece Donovan, CEO, Mayden says: “I’m delighted to welcome the Wellola team to Mayden. Portasana adds a powerful, integrated patient engagement platform to our growing portfolio, giving our customers the tools they need to improve access, streamline care, and empower patients to manage their own health safely.Mayden and Wellola hold a shared belief that technology should not only support services to be more efficient, but also make care more meaningful for the people who rely on it. Together, we can reach further and make a bigger impact for both services and the people they serve”Sonia Neary, co-founder of Wellola, says: “Joining Mayden is an exciting step for our team. We’ve always believed that giving people the right tools to understand and manage their own health leads to better outcomes, less pressure on clinicians, and more sustainable services.Being part of Mayden allows us to scale this vision more effectively and support more health and care providers and patients.”Source: <a href="https://www.mayden.com/blog/press-releases/mayden-expands-its-digital-health-portfolio-with-portasana/">https://www.mayden.com/blog/press-releases/mayden-expands-its-digital-health-portfolio-with-portasana/</a>

Nelson Advisors served as exclusive advisors to Wellola on their sale to  Mayden, backed by G Square Capital

FemTech startup Daye has been announced as the winner of the Digital Health Rewired Pitchfest 2026 competition following the live final held at Rewired 2026 at the NEC, Birmingham.What Daye does Daye is a women’s health biotech focused on closing the gender health gap through science-led innovation. Its flagship product is the Daye Diagnostic Tampon, which turns a familiar menstrual product into an at-home tool for detecting high‑risk HPV, the leading cause of cervical cancer. About the Pitchfest 2026 win Pitchfest is Digital Health Rewired’s startup competition, offering finalists exposure to NHS digital leaders, investors, and potential NHS pilot partners. For 2026, 16 startups were shortlisted, eight progressed to the live final, and Daye was selected as overall winner after pitching against other digital health innovators such as Astron Health and Cogniss. The winner receives advisory support and the opportunity for a potential NHS pilot with CW+ and Chelsea and Westminster Hospital, giving Daye a route to scale adoption in the NHS. Why judges backed Daye Judges and organisers highlighted Daye’s strong potential to make a real impact in healthcare by reducing barriers to cervical cancer screening through at-home HPV testing. Daye’s founder, Valentina Milanova, framed the solution as a way to turn the UK’s strong science base into delivery at scale, with the aim of contributing to the eradication of cervical cancer and delivering returns both in lives saved and health system savings.Judging PanelJon Hoeksma, chief executive of Future Health Intelligence Mindy Simon, co-director of NHS Innovation Accelerator Michael Morgan-Curran, chief executive of Asclepius MedTech Limited Lloyd Price, partner at Nelson Advisors Sara Nelson, programme director at DigitalHealth.London Pei-Fen Lin, clinical director of innovation at Moorfields Eye Hospital Chris Sawyer, innovation lead – digital health at Innovate UK The other finalists who competed in the Pitchfest 2026 live final were:Astron Health Cogniss Into-Action.Health, Jigsaw Medical LightHearted AI Mavis Technologies Upskill.HealthSource: <a href="https://www.digitalhealth.net/2026/03/daye-announced-as-rewired-pitchfest-2026-winner/">https://www.digitalhealth.net/2026/03/daye-announced-as-rewired-pitchfest-2026-winner/</a> &nbsp; &nbsp; &nbsp; &nbsp;

Nelson Advisors

Blog

The Data Primacy Shift: Proprietary Health Datasets as th...

Navigating Share Purchase Agreements versus Asset Purchas...

Nelson Advisors Conferences and Events 2026

Nelson Advisors advised the Clinic Letter AI founders on...

Nelson Advisors served as exclusive advisors to Wellola o...

FemTech startup Daye wins Digital Health Rewired Pitchfes...